Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

7 Studies show the use of Dexcom glucose biosensing by people with Type 2 diabetes is associated with clinically meaningful improvement in time in range, A1c and quality of life.8-11 Stelo is now ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San ...

DexCom's CGM devices are compatible with other gadgets and apps. Devices compatible with DexCom's G6, G7, or DexCom ONE include Tandem Diabetes Care t:slim X2, Insulet Omnipod 5, some of Eli Lilly ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...